US researchers evaluated the use of the drug on 38 women who were experiencing sexual dysfunction while being treated with nonselective serotonin reuptake inhibitors (SRIs).
They were randomly assigned sildenafil or placebo at a flexible does starting at 50 mg adjustable to 100 mg before sexual activity over an eight week period.
When assessed on the Clinical Global Impression sexual function scale, those on sildenafil had a mean score of 1.9, compared with 1.1 in the placebo group.
Authors wrote: ‘In the study population, sildenafil treatment of sexual dysfunction in women taking SRIs was associated with a reduction in adverse sexual effects.’
JAMA (2008) 300:395-404